ID

35340

Descrição

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02491398

Link

https://clinicaltrials.gov/show/NCT02491398

Palavras-chave

Versões (1)
  1. 28/02/2019 28/02/2019 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

28 de fevereiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

  • Os mais recentes
  • Os mais antigos
  • Preferidos
  • Os mais recentes
    • Os mais recentes
    • Os mais antigos
    • Preferidos

Sem comentários

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Chronic Lymphocytic Leukemia NCT02491398

Inglês

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
Descrição

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1302547
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
Descrição

Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1328232
UMLS CUI [1,2]
C1708063
UMLS CUI [2,1]
C1328232
UMLS CUI [2,2]
C1710038
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
Descrição

Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0023434
UMLS CUI [2,2]
C0332121
UMLS CUI [3,1]
C1328232
UMLS CUI [3,2]
C0750729
UMLS CUI [3,3]
C1265611
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
Descrição

Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0023434
UMLS CUI [2]
C0002073
UMLS CUI [3]
C1268902
UMLS CUI [4]
C0003250
UMLS CUI [5,1]
C0003250
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C0686904
UMLS CUI [6,2]
C1710038
UMLS CUI [7,1]
C1328232
UMLS CUI [7,2]
C0750729
UMLS CUI [7,3]
C1265611
age ≥ 18 years old.
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
signed written informed consent according to ich/eu/gcp and national local law.
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received 2 or more lines of prior therapy.
Descrição

Prior Therapy Quantity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
patients with:
Descrição

Patients Have

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C3539897
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
Descrição

Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1142081
UMLS CUI [1,2]
C1332225
UMLS CUI [2]
C0349631
UMLS CUI [3]
C0019693
UMLS CUI [4,1]
C0019196
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0019163
UMLS CUI [5,2]
C0205318
UMLS CUI [6,1]
C0023890
UMLS CUI [6,2]
C0205318
Voltar ao início da página

Similar models

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Item
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
boolean
C1302547 (UMLS CUI [1])
Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment
Item
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
boolean
C1328232 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C1328232 (UMLS CUI [2,1])
C1710038 (UMLS CUI [2,2])
Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity
Item
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
boolean
C1514463 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0023434 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1328232 (UMLS CUI [3,1])
C0750729 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity
Item
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
boolean
C1514463 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C0002073 (UMLS CUI [2])
C1268902 (UMLS CUI [3])
C0003250 (UMLS CUI [4])
C0003250 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0686904 (UMLS CUI [6,1])
C1710038 (UMLS CUI [6,2])
C1328232 (UMLS CUI [7,1])
C0750729 (UMLS CUI [7,2])
C1265611 (UMLS CUI [7,3])
Age
Item
age ≥ 18 years old.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
signed written informed consent according to ich/eu/gcp and national local law.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy Quantity
Item
patients who have received 2 or more lines of prior therapy.
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Patients Have
Item
patients with:
boolean
C0030705 (UMLS CUI [1,1])
C3539897 (UMLS CUI [1,2])
Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled
Item
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
boolean
C1142081 (UMLS CUI [1,1])
C1332225 (UMLS CUI [1,2])
C0349631 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
C0019196 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0019163 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0023890 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Voltar ao início da página 

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial